Vera Therapeutics(NASDAQ) VERA

Vera Therapeutics, Inc. makes medicines for people with serious kidney diseases. These drugs stop the immune system from attacking healthy organs. Patients can easily take these treatments at home with self-injectors.

New Help for Kidney Patients

• TRUTAKNA: Self-administered injection that reduces protein in urine for adults with IgAN kidney disease.
• Product Pipeline: Clinical programs testing the main drug for multiple autoimmune kidney and systemic diseases.
• MAU868: Monoclonal antibody designed to treat reactivated infections caused by the BK virus.
• VT-109: Preclinical-stage medicine that targets proteins responsible for activating harmful B cells.

Expanding the Medicine Pipeline

• Acquired worldwide rights to VT-109, a next-generation inhibitor for autoimmune diseases, in January 2025.
• Refinanced existing debt in June 2025 to secure up to $500 million in term loans.
• Raised approximately $281.3 million through a follow-on public offering of common stock in December 2025.
• Received accelerated FDA approval for TRUTAKNA on July 7, 2026, for adults with IgAN kidney disease.

How Vera Targets Disease

Vera focuses on dual inhibitors that target two specific proteins, BAFF and APRIL, which drive many autoimmune conditions. This approach allows the company to test one drug across many different immune-related diseases.

Key Financial Figures

• Net loss was $109.5 million for the three-month period ended June 30, 2026.
• General and administrative expenses rose 139% to $52.4 million in the second quarter of 2026.
• Research and development spending increased 47% to $146.1 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $499.2 million as of June 30, 2026.

Bottom Line

Vera has moved from a research firm to a commercial company following its first drug approval in 2026. It continues to expand its pipeline to address a wide range of autoimmune disorders.